Sclerosis: all 3,103 studies

Page 9 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.

• An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple SclerosisCompletedNCT00670449Phase 2Results posted
• Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated SyndromeCompletedNCT00666224Phase 3Results posted
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00662649Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3Results posted
• Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3Results posted
• Investigation of Simvastatin in Secondary Progressive Multiple SclerosisCompletedNCT00647348Phase 2Results posted
• Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00647296Phase 2Results posted
• A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)TerminatedNCT00642902Phase 2Results posted
• CLARITY Extension StudyCompletedNCT00641537Phase 3Results posted
• Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00640328Phase 2Results posted
• Memantine for Spasticity in MS PatientsCompletedNCT00638027Phase 4Results posted
• Allogeneic Hematopoietic Cell Transplantation for Severe Systemic SclerosisCompletedNCT00622895Phase 1/2Results posted
• Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple SclerosisCompletedNCT00622700Phase 3Results posted
• Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical TrialsCompletedNCT00620698Results posted
• Transition to Rebif New FormulationCompletedNCT00619307Phase 3Results posted
• Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic SclerosisCompletedNCT00613171Phase 2Results posted
• Locomotor Training in Persons With Multiple SclerosisCompletedNCT00607126Phase 1/2Results posted
• BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedNCT00605215Phase 3Results posted
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple SclerosisTerminatedNCT00595920Phase 2Results posted
• Teleconference Fatigue Management for People With Multiple SclerosisCompletedNCT00591721Not applicableResults posted
• Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisCompletedNCT00555581Phase 2Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedNCT00548405Phase 3Results posted
• Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral SclerosisTerminatedNCT00537446Not applicableResults posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT00537082Phase 2Results posted
• The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisCompletedNCT00536120Phase 4Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneCompletedNCT00530348Phase 3Results posted
• Natalizumab High Titer Immunogenicity and SafetyCompletedNCT00516893Phase 2Results posted
• A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic SclerosisCompletedNCT00512902Phase 1/2Results posted
• Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT00509145Phase 3Results posted
• Neuroprotection With Riluzole Patients With Early Multiple SclerosisCompletedNCT00501943Phase 2Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple SclerosisCompletedNCT00489489Phase 2Results posted
• Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple SclerosisCompletedNCT00475865Phase 2Results posted
• Rebif New Formulation (RNF) Quality of Life (QOL) StudyCompletedNCT00472797Phase 3Results posted
• Aspirin for Treatment of Multiple Sclerosis-Related FatigueTerminatedNCT00467584Phase 3Results posted
• BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DoseCompletedNCT00459667Phase 3Results posted
• A Study to Test the Use of Duloxetine for Pain in MSCompletedNCT00457730Phase 2/3Results posted
• A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT00451204Phase 2Results posted
• A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisCompletedNCT00441103Phase 3Results posted
• A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)CompletedNCT00436826Phase 2Results posted
• RNF and Betaseron® Tolerability StudyCompletedNCT00428584Phase 3Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis AttacksTerminatedNCT00418145Phase 3Results posted
• Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple SclerosisTerminatedNCT00414453Phase 4Results posted
• Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1/2Results posted
• Testosterone Treatment for Multiple SclerosisCompletedNCT00405353Phase 1/2Results posted
• REbif FLEXible Dosing in Early Multiple Sclerosis (MS)CompletedNCT00404352Phase 3Results posted
• Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MSCompletedNCT00391079Phase 3Results posted
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00390221Phase 2Results posted
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyCompletedNCT00381940Phase 2Results posted
• Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisCompletedNCT00370071Phase 3Results posted
• Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple SclerosisCompletedNCT00367484Phase 4Results posted
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00355134Phase 3Results posted
• Clinical Trial Ceftriaxone in Subjects With ALSCompletedNCT00349622Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseCompletedNCT00340834Phase 3Results posted
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).CompletedNCT00337779Phase 3Results posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple SclerosisCompletedNCT00333138Phase 2Results posted
• Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00326625Phase 2Results posted
• Cognitive-behavior Therapy for MS-Related Chronic PainCompletedNCT00323271Not applicableResults posted
• Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifCompletedNCT00317941Phase 4Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00289978Phase 3Results posted
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyCompletedNCT00288626Phase 2Results posted
• Hematopoietic Stem Cell Therapy for Patients With Multiple SclerosisTerminatedNCT00278655Phase 1/2Results posted
• Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized StudyCompletedNCT00273364Phase 2Results posted
• Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis PatientsCompletedNCT00262314Results posted
• Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple SclerosisCompletedNCT00246324Phase 4Results posted
• Clinical Trial of High Dose CoQ10 in ALSCompletedNCT00243932Phase 2Results posted
• Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple SclerosisCompletedNCT00235989Phase 2Results posted
• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple SclerosisCompletedNCT00220779Phase 2Results posted
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxCompletedNCT00211887Phase 3Results posted
• A Safety and Efficacy Study of CNTO1275 in Patients With Multiple SclerosisCompletedNCT00207727Phase 2Results posted
• Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedNCT00203047Phase 4Results posted
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedNCT00203021Phase 4Results posted
• BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyCompletedNCT00185211Phase 3Results posted
• Long Term Study of Avonex Therapy Following a First Attack of Multiple SclerosisCompletedNCT00179478Phase 4Results posted
• Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRICompletedNCT00176592Phase 4Results posted
• Stress Management for Patients With Multiple SclerosisCompletedNCT00147446Phase 2Results posted
• Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple SclerosisCompletedNCT00134563Phase 3Results posted
• Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3Results posted
• Fish Oil for the Treatment of Depression in Patients With Multiple SclerosisCompletedNCT00122954Phase 1/2Results posted
• Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure VentilationCompletedNCT00116558Not applicableResults posted
• Scleroderma: Cyclophosphamide or TransplantationCompletedNCT00114530Phase 2/3Results posted
• Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisCompletedNCT00110396Phase 3Results posted
• Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisCompletedNCT00094172Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2/3Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2Results posted
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisCompletedNCT00050778Phase 2Results posted
• Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) TrialCompletedNCT00035815Phase 3Results posted
• Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple SclerosisSuspendedNCT07146087Early Phase 1
• Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS PatientsCompletedNCT07002151Not applicable
• The Effect of Task-Oriented Training and Virtual Reality Training on Balance, Gait and Fatigue in Individuals With Multiple SclerosisCompletedNCT07000968Not applicable
• The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MSCompletedNCT06987994Not applicable
• An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADCompletedNCT06987851Phase 3
• Trunk Restraint in Multiple SclerosisCompletedNCT06982833Not applicable
• Laughter Yoga for Improving Sexual Function and Psychosocial Outcomes in Multiple SclerosisCompletedNCT06947434Not applicable

← Sclerosis overview